

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

**INSIDE INFORMATION ANNOUNCEMENT
APPROVAL BY THE CSRC OF
H SHARE FULL CIRCULATION APPLICATION OF THE COMPANY**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

References are made to the inside information announcement dated June 30, 2022, the circular dated July 29, 2022, the announcement on the poll results of the EGM dated August 15, 2022 and the announcement on the acceptance of application dated August 25, 2022 (the “**Announcements and Circular**”) in relation to, among others, the particulars of the Company’s H Share Full Circulation Application and the acceptance by the China Securities Regulatory Commission (the “**CSRC**”) of H Share Full Circulation Application of the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements and Circular.

The Company is pleased to announce that on November 10, 2022, the Company received the Reply of the Approval on the Overseas Listing of Domestic Unlisted Shares of Jiangsu Recbio Technology Co., Ltd. (《關於核准江蘇瑞科生物技術股份有限公司境內未上市股份到境外上市的批覆》) from the CSRC (the “**Reply**”), pursuant to which the CSRC approved 46 Shareholders of the Company to convert a total of 222,498,569 domestic unlisted Shares held by them into overseas listed Shares, which can be listed and traded on the Main Board of the Stock Exchange upon completion of the conversion (the “**Conversion and Listing**”). The Reply shall be valid for 12 months from the approval date (November 3, 2022). Please refer to the Announcements and Circular for details of names of Shareholders and number of Shares applied for full circulation.

As at the date of this announcement, the details of the implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, November 10, 2022

As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive Director, Dr. Chen Jianping and Mr. Li Bu as executive Directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive Directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive Directors.